General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-20 | 2024-03 | -3.33 | -9.14 | -5.81 | -174.47% |
2024-04-02 | 2023-12 | -17.14 | N/A | N/A | N/A |
2023-11-14 | 2023-09 | -5.99 | N/A | N/A | N/A |
2023-11-14 | 2023-09 | -5.99 | -48.77 | -42.78 | -714.19% |
2023-08-14 | 2023-06 | -115.6 | -36.8 | 78.8 | 68.17% |
2023-08-14 | 2023-06 | -115.6 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-05 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-07-18 | ALBANNA AMRO A | Officer | 1.00 | Purchase |
2021-06-03 | ALBANNA ROWENA | Chief Operating Officer | 0.00 | Stock Award(Grant) |
2023-09-06 | BNP PARIBAS SECURITIES CORPORATION NORTH AMERICA | Unknown | 22.34K | Sale |
2021-05-25 | FARLEY THOMAS J | Officer | 2.50K | Purchase |
2020-07-21 | KIAIE NAMVAR | Director | 2.22K | Conversion of Exercise of derivative security |
2021-06-03 | PANKOVCIN CORINNE D | Chief Financial Officer | 169.22K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Sabby Management, LLC | 14.74K | 265.30K | 6.17% |
2023-06-29 | Vanguard Group Inc | 1.16K | 20.92K | 0.49% |
2023-09-29 | IFP Advisors, Inc | 1.08K | 13.53K | 0.45% |
2023-06-29 | State Street Corporation | 948.00 | 17.06K | 0.40% |
2023-06-29 | Natixis | 250.00 | 4.50K | 0.10% |
2023-06-29 | Tower Research Capital LLC (TRC) | 246.00 | 4.43K | 0.10% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Extended Market Index Fund | 1.16K | 20.92K | 0.49% |
2023-05-30 | Fidelity Extended Market Index Fund | 39.00 | 951.00 | 0.02% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 44.00 | 1.07K | 0.02% |
2023-05-30 | Fidelity Series Total Market Index Fund | 18.00 | 439.00 | 0.01% |
Split | Date |
---|---|
1 : 40 | 2023-08-18 |
1 : 50 | 2022-09-14 |
1 : 50 | 2022-09-12 |
What is happening with this pure POS company?
Tomorrow
Tomorrow
When there are no news, but promisses… of course that is not good. I will never sell my POS stocks because I have lost 98% of my investments. This company should be investigated as well as the senior management and the main shareholders. Where is the Dawson’s analyst?
Tomorrow
Tomorrow
POS today, tomorrow e forever.
Tomorrow
Tomorrow
Acquistion of USD55MM?? issuing USD200MM in stocks?? I can not understand what can not be explained.
Tomorrow, for God’s sake. LOL
Tomorrow
Tomorrow
Tomorrow
Never give up
I read the 10K and my conclusion is that the senior management was irrespondible to say at least. Cellvera received only USD14,5MM without any collaterall. After made an agreement to receive up to USD30MM of Cellvera’s revenue ( estimated USD150MM annual - I do not believe at all). Again Cellvera did no transfer any USD. So, Aditx has lost 100% of the USD14,5MM. Now, Aditxt will distribute Favipiravir from Cellvera. Seriously?
Last year the revenue was USD993k, but I was not able to see the breakdown. Aditx wants to acquire some Lucira (covid test!!) For what? Now that covid is not a concern? Where is the money to buy it?
AditxScore, Is it a joke? The company should least provide more details to the shareholders.
Merck has just acquired Prometheus for USD10,8B which does not have any FDA approved product yet.
The company is “promissing immune disease treatments”. If ADTX has someting real must do the same. Let’s see
Ben, from where did you get this crazy idea?
Lol
Total lack of transparency and respect from senior management.
This company is dead money. Garbage